trending Market Intelligence /marketintelligence/en/news-insights/trending/JeRr8-s_A8xDV_jtLAKgTQ2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Amicus Therapeutics starts $150M offering to fund gene therapy pipeline


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates


COVID-19 Impact & Recovery: Investment Banking

Amicus Therapeutics starts $150M offering to fund gene therapy pipeline

Amicus Therapeutics Inc. said it started a common stock offering to raise $150 million.

Net proceeds will go toward development of the company's expanded gene therapy pipeline and manufacturing capabilities for Pompe biologic AT-GAA and gene therapy product candidates, including contract manufacturing partnerships.

A portion of the proceeds is also allotted for the completion of the design and build of the Amicus process science and gene therapy manufacturing facility, as well as for other general corporate and product development purposes.

Underwriters will have an option to buy up to an additional 15% of the common shares being offered in the transaction.

Cranbury, N.J.-based Amicus Therapeutics discovers and develops medicine for rare metabolic diseases.

J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and SVB Leerink LLC are acting as joint book-running managers in the offering.